Grapy publishes joint research with KAIST in international journal on next-gen 3D printing medical materials

Grapy, a South Korean additive manufacturing materials company, has published joint research with KAIST in the international journal Virtual and Physical Prototyping. The study demonstrates that functionalized cellulose nanocrystals derived from plant-based biomaterials, when added at ultra-low concentrations to photocurable elastic resin, increase tensile strength by up to 173% while also improving elongation and toughness. The team validated the technology by 3D printing patient-specific biliary stents and kidney cancer resection guides, confirming print stability and elastic properties. Grapy senior researcher Kim Hoon stated the work establishes a clear technical foundation for the company's symbiotic material platform technology on a global stage.

This publication matters because it targets the intersection of biomaterials and medical device manufacturing, a segment where material qualification and biocompatibility are the primary barriers to adoption. Grapy's approach — using functionalized cellulose nanocrystals as a reinforcing additive in photocurable resins — addresses a persistent gap in vat photopolymerization (VPP) for medical applications: the trade-off between printability and mechanical performance. Most commercial medical-grade resins for SLA/DLP systems offer limited elongation or toughness, making them unsuitable for flexible implants like biliary stents. By achieving a 173% tensile strength improvement with minimal additive loading, Grapy positions itself against established medical resin suppliers such as Formlabs (BioMed series), Stratasys (MED series), and 3D Systems (Figure 4 MED). The research also aligns with broader industry trends toward bio-based, sustainable materials in medical AM, though the path from peer-reviewed publication to regulatory clearance (MFDS, FDA 510(k), CE-MDR) remains long and uncertain.

From a practical standpoint, this is a materials science validation, not a commercial product launch. Grapy must now demonstrate that the cellulose-nanocrystal-reinforced resin can be manufactured at scale, maintain batch-to-batch consistency, and pass biocompatibility testing under ISO 10993 standards. For medical device manufacturers evaluating this technology, the key next step is to request test coupons and conduct internal validation against existing approved materials. The publication strengthens Grapy's technical credibility but does not yet shorten the qualification timeline required for clinical adoption.